Published in Prostate on January 01, 2000
Low-Fat Fish Oil Diet for Prostate Cancer Prevention | NCT00798876
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A (2003) 2.40
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol (2015) 1.65
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50
Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer (2004) 1.44
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab (2001) 1.31
Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol Cancer (2006) 1.18
TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology (2013) 1.16
Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med (2014) 1.12
COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer (2007) 1.11
Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia (2001) 1.08
Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One (2011) 1.07
Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer (2004) 1.07
1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics (2010) 1.05
Trichomonas vaginalis adherence mediates differential gene expression in human vaginal epithelial cells. Cell Microbiol (2005) 1.04
Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol (2010) 1.02
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia (2007) 1.01
Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis (2002) 1.01
Association of the innate immunity and inflammation pathway with advanced prostate cancer risk. PLoS One (2012) 1.01
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia (2001) 1.00
Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol (2004) 1.00
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila) (2010) 0.98
Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: a study from northern India. World J Gastroenterol (2008) 0.97
Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res (2014) 0.96
Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer (2012) 0.96
High-fat diet increases NF-κB signaling in the prostate of reporter mice. Prostate (2011) 0.96
Aspirin and urologic cancer risk: an update. Nat Rev Urol (2012) 0.91
Nonsteroidal anti-inflammatory drugs and prostatic diseases. Biomed Res Int (2014) 0.91
The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Rev (2011) 0.91
Gene Therapy Applications to Cancer Treatment. J Biomed Biotechnol (2003) 0.90
Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer (2009) 0.89
Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol (2012) 0.89
Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis (2004) 0.89
Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res (2009) 0.89
The eicosanoid cascade: possible role in gliomas and meningiomas. J Clin Pathol (2004) 0.89
Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation. Clin Exp Metastasis (2009) 0.88
Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. J Nutrigenet Nutrigenomics (2009) 0.88
-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol (2006) 0.88
Anti-inflammatory activity of soy and tea in prostate cancer prevention. Exp Biol Med (Maywood) (2010) 0.87
α(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma. Am J Transl Res (2012) 0.87
Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. Br J Cancer (2014) 0.86
Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States. Dig Dis Sci (2006) 0.85
Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br J Cancer (2002) 0.85
Epidural analgesia during open radical prostatectomy does not improve long-term cancer-related outcome: a retrospective study in patients with advanced prostate cancer. PLoS One (2013) 0.85
Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study. Radiat Oncol (2006) 0.84
Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality. Cancers (Basel) (2012) 0.84
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer (2007) 0.84
Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model. BMC Urol (2013) 0.83
Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluorocoxib A. Neoplasia (2015) 0.83
Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. Pancreas (2011) 0.83
The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. Biologics (2008) 0.82
Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis. Korean J Intern Med (2010) 0.81
Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer. Prostate (2012) 0.81
Chemoprevention strategies in the prostate: an overview. Rev Urol (2002) 0.81
Flaxseed reduces the pro-carcinogenic micro-environment in the ovaries of normal hens by altering the PG and oestrogen pathways in a dose-dependent manner. Br J Nutr (2015) 0.80
Blood level omega-3 Fatty acids as risk determinant molecular biomarker for prostate cancer. Prostate Cancer (2013) 0.80
Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells. BMC Mol Biol (2011) 0.79
Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells. Oral Maxillofac Surg (2010) 0.79
Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans. Front Immunol (2016) 0.78
Inflammatory suppressive effect of prostate cancer cells with prolonged exposure to transforming growth factor β on macrophage-differentiated cells via downregulation of prostaglandin E2. Oncol Lett (2014) 0.78
Post-translational regulation of COX2 activity by FYN in prostate cancer cells. Oncotarget (2014) 0.78
Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermatoendocrinol (2009) 0.77
Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. BMC Cancer (2014) 0.77
Strategies for prostate cancer prevention: Review of the literature. Indian J Urol (2008) 0.77
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. Invest New Drugs (2016) 0.76
Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. PLoS One (2016) 0.76
Association between polymorphisms in selected inflammatory response genes and the risk of prostate cancer. Onco Targets Ther (2016) 0.76
Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma. Oncotarget (2015) 0.76
Inhibition mechanism of the intracellular transporter Ca2+-pump from sarco-endoplasmic reticulum by the antitumor agent dimethyl-celecoxib. PLoS One (2014) 0.76
Cyclooxygenase-2 is associated with malignant phenotypes in human lung cancer. Oncol Lett (2016) 0.75
Prostaglandin-endoperoxide synthase 2 (PTGS2) rs20417 polymorphism and prostate cancer risk: a meta analysis. Int J Clin Exp Med (2015) 0.75
The association between regular use of aspirin and the prevalence of prostate cancer: Results from the National Health Interview Survey. Medicine (Baltimore) (2016) 0.75
Synthesis and Evaluation of Cytosolic Phospholipase A2 Activatable Fluorophores for Cancer Imaging. Bioconjug Chem (2015) 0.75
Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer. Pharmaceuticals (Basel) (2010) 0.75
Hormophysa triquerta polyphenol, an elixir that deters CXCR4- and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells. Oncotarget (2016) 0.75
Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer. Mol Clin Oncol (2017) 0.75
Roles of Eicosanoids in Prostate Cancer. Future Lipidol (2008) 0.75
Saturated fatty acids up-regulate COX-2 expression in prostate epithelial cells via toll-like receptor 4/NF-κB signaling. Inflammation (2014) 0.75
COX-2 inhibitors in prostate cancer treatment--hold your horses? Asian J Androl (2012) 0.75
Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms. Front Pharmacol (2017) 0.75
Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. BMC Urol (2017) 0.75
Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism. Surgery (2017) 0.75
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis. Oncogene (2017) 0.75
Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice. Oncogene (2017) 0.75
Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas. Mol Cancer (2017) 0.75
Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. Cancer Med (2017) 0.75
Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer. Inflammopharmacology (2016) 0.75
Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ (1999) 6.40
Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997) 3.85
Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis (1998) 3.05
Accuracy of frozen-section diagnosis of mammographically directed breast biopsies. Results of 1,490 consecutive cases. Am J Surg Pathol (1995) 3.02
The focus of "atypical glands, suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol (1997) 2.98
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80
Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A (2001) 2.79
A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics (1997) 2.65
Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr (2000) 2.52
Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst (1997) 2.39
Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol (1997) 2.33
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Green tea and skin. Arch Dermatol (2000) 2.29
Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer (2000) 2.28
Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol (1998) 2.14
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 2.04
Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol (1996) 2.04
Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate (1999) 2.02
Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol (1986) 2.01
During infection of epithelial cells Salmonella enterica serovar Typhimurium undergoes a time-dependent transcriptional adaptation that results in simultaneous expression of three type 3 secretion systems. Cell Microbiol (2007) 1.94
Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure. J Virol (1990) 1.94
Inflammatory pseudotumor and sarcoma of urinary bladder: differential diagnosis and outcome in thirty-eight spindle cell neoplasms. Mod Pathol (2001) 1.92
Artificial neural networks improve the accuracy of cancer survival prediction. Cancer (1997) 1.91
A transcriptional insulator at the imprinted H19/Igf2 locus. Genes Dev (2000) 1.88
Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85
Accuracy of frozen section diagnosis in surgical pathology: review of a 1-year experience with 24,880 cases at Mayo Clinic Rochester. Mayo Clin Proc (1995) 1.84
Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer (1987) 1.79
Patterns of progression in prostate cancer. Lancet (1986) 1.78
Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res (1996) 1.78
Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol (1994) 1.73
Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci U S A (1999) 1.72
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst (1999) 1.70
The timing of calcium measurements in helping to predict temporary and permanent hypocalcaemia in patients having completion and total thyroidectomies. Ann R Coll Surg Engl (2009) 1.69
Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus. J Virol (1988) 1.67
The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA (1996) 1.65
The biosynthesis of some androst-16-enes from C21 and C19 steroids in boar testicular and adrenal tissue. Biochem J (1968) 1.64
Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys (2000) 1.63
Low-grade collecting duct carcinoma of the kidney: report of 13 cases of low-grade mucinous tubulocystic renal carcinoma of possible collecting duct origin. Urology (1997) 1.63
Prostatic adenocarcinoma with glomeruloid features. Hum Pathol (1998) 1.63
Expression of early growth response genes in human prostate cancer. Cancer Res (1998) 1.62
Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer (1998) 1.61
Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol (1999) 1.61
Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. Hum Pathol (1994) 1.59
Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer (1999) 1.59
Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer (2001) 1.58
Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res (1999) 1.58
Villous adenoma of the urinary tract: a report of 23 cases, including 8 with coexistent adenocarcinoma. Am J Surg Pathol (1999) 1.58
Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene (2007) 1.57
Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology (1998) 1.57
Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol (2000) 1.55
Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: A new proposal. Cancer (1999) 1.54
Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res (1995) 1.52
Comparison of renal ablation with cryotherapy, dry radiofrequency, and saline augmented radiofrequency in a porcine model. J Am Coll Surg (2001) 1.52
Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl (1995) 1.52
Green tea polyphenols and cancer: biologic mechanisms and practical implications. Nutr Rev (1999) 1.51
Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst (1997) 1.51
Is there a correlation between 18F-FDG-PET standardized uptake value, T-classification, histological grading and the anatomic subsites in newly diagnosed squamous cell carcinoma of the head and neck? Eur Arch Otorhinolaryngol (2010) 1.50
Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology (1997) 1.50
Functional and antigenic characterization of human, rhesus macaque, pigtailed macaque, and murine DC-SIGN. J Virol (2001) 1.48
Green tea polyphenol (-)-epigallocatechin-3-gallate treatment of human skin inhibits ultraviolet radiation-induced oxidative stress. Carcinogenesis (2001) 1.48
Tea in chemoprevention of cancer. Int J Oncol (1996) 1.47
Genetic variation in low-dose UV-induced suppression of contact hypersensitivity and in the skin photocarcinogenesis response. J Invest Dermatol (1997) 1.47
Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol (1997) 1.46
'I can't do any serious exercise': barriers to physical activity amongst people of Pakistani and Indian origin with Type 2 diabetes. Health Educ Res (2005) 1.46
Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res (2001) 1.43
Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc (1998) 1.42
Malignant lymphoma of the bladder: evidence from 36 cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma. Am J Surg Pathol (1997) 1.42
Green tea in chemoprevention of cancer. Toxicol Sci (1999) 1.41
Loss of heterozygosity on chromosome 13 is associated with advanced stage prostate cancer. J Urol (1999) 1.41
Green tea polyphenol (-)-epigallocatechin-3-gallate treatment to mouse skin prevents UVB-induced infiltration of leukocytes, depletion of antigen-presenting cells, and oxidative stress. J Leukoc Biol (2001) 1.41
Risk of malignancy in resected cystic tumors of the pancreas < or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. J Gastrointest Surg (2007) 1.39
Specific high-affinity binding of fatty acids to epidermal cytosolic proteins. J Invest Dermatol (1991) 1.38
Leiomyosarcoma of the prostate. Report of 23 cases. Cancer (1995) 1.38
Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine (2010) 1.37
cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev (1996) 1.36
Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol (1985) 1.36
Whipple's disease presenting as aortic insufficiency. N Engl J Med (1981) 1.36
Cardiac metastases from soft-tissue sarcomas. J Clin Oncol (1986) 1.36
Inhibition of UVB-induced oxidative stress-mediated phosphorylation of mitogen-activated protein kinase signaling pathways in cultured human epidermal keratinocytes by green tea polyphenol (-)-epigallocatechin-3-gallate. Toxicol Appl Pharmacol (2001) 1.35
Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol (1999) 1.35
Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol (2001) 1.34
Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the "vanishing cancer phenomenon". Am J Surg Pathol (1995) 1.33
Studies on the biosynthesis of 16-dehydro steroids. The metabolism of [4-14C]pregnenolone by boar adrenal and testis tissue in vitro. Biochem J (1967) 1.33
Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol (1995) 1.33
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene (2008) 1.33
Paraganglioma of the urinary bladder: can biologic potential be predicted? Cancer (2000) 1.33
Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. J Clin Invest (1985) 1.33
Calcium channel activity of purified human synexin and structure of the human synexin gene. Proc Natl Acad Sci U S A (1989) 1.33
Squamous papilloma of the urinary tract is unrelated to condyloma acuminata. Cancer (2000) 1.32
Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res (1985) 1.32
Analysis of membrane protein cluster densities and sizes in situ by image correlation spectroscopy. Faraday Discuss (1998) 1.31
Role of clinical, radiological, and neurophysiological changes in predicting the outcome of tuberculous meningitis: a multivariable analysis. J Neurol Neurosurg Psychiatry (2000) 1.29
Photodynamic therapy in dermatology. J Am Acad Dermatol (2000) 1.28
Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res (1996) 1.28
Hemangioma of the urinary bladder. Cancer (1999) 1.28